Massive Bio, an AI-driven clinical trial matching platform provider, has partnered with Foundation Medicine, a leader in next-gen sequencing, to increase patient access to cancer clinical trials.
The collaboration aims to address the low rate of patient enrollment in oncology clinical trials by combining Massive Bio's AI-driven patient-matching technology with Foundation Medicine's expertise in genomic profiling. The partnership will leverage shared data and AI analytics to enhance clinical trial matching speed and accuracy, potentially improving patient outcomes globally.
Through this partnership, both companies aim to use their networks and capabilities across the healthcare landscape, employing advanced AI techniques and a robust digital health platform to refine clinical trial processes and enhance precision oncology.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.